ScreenerHero

FBLGFibroBiologics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · fibrobiologics.com
1.440USD+21.01%Mkt Cap: 9.59M $P/E: —

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline in…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap9.59M $
Enterprise Value6.54M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-18.65M $
Revenue/Share—
Last Price1.440 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.40
PEG—
EV/EBITDA-0.40
EV/Revenue—
P/S—
P/B1.69
EPS (TTM)-5.51
EPS (Forward)-3.25
52W Range
0.62017% of range12.80
52W High12.80 USD
52W Low0.6201 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-302.89%
ROA-193.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.39M $
CapEx (TTM)262.00K $
FCF Margin—
FCF Yield-87.28%
Net Debt-2.05M $
Net Debt/EBITDA0.12
Balance Sheet
Debt/Equity0.39
Current Ratio2.64
Quick Ratio1.59
Book Value/Sh0.7620 USD
Cash/Share0.5280 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateMar 30, 2026
Analyst Consensus
Rating—
Target (Mean)12.50 USD
Upside (mean)+768.1%
Target Range6.000 USD – 19.00 USD
$6.000+768.1% to mean$19.00
# Analysts2
Ownership
Shares Out.6.66M
Float6.00M
Insiders9.87%
Institutions15.53%
Short Interest
Short Ratio1.3d
Short % Float1.82%
Short % Out.1.73%
Shares Short115.20K
Short (prev mo.)135.79K
Technical
SMA 500.8721 (+65.1%)
SMA 2003.555 (-59.5%)
Beta1.22
S&P 52W Chg18.16%
Avg Vol (30d)161.30K
Avg Vol (10d)251.01K
Technical Indicators
RSI (14)75.6
MACD0.1033
MACD Signal0.0502
MACD Hist.+0.0530
BB Upper1.351 USD
BB Middle0.9128 USD
BB Lower0.4742 USD
BB Width96.10%
ATR (14)0.1256 USD
Vol Ratio (20d)3.15x